Menu
Washingtoner
  • Home
  • Financial
  • Home
  • Technology
  • Education
  • Business
  • Services
  • Non-profit
  • Construction
Washingtoner

Orlance, Inc. awarded RNA Vaccine Development Grant
Washingtoner/10263081

Trending...
  • Spokane City Council Members Introduce "Immigration Enforcement Free Zones"
  • City of Tacoma Offers In-Person Workshop for Local Businesses on the Revolving Loan Fund Process
  • City Council Confirms Appointment of Patti Jackson as Tacoma's Police Chief
SEATTLE, July 10, 2024 ~ Seattle-based biotech company, Orlance, Inc., has recently been granted a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The grant, worth $300,000 per year for two years, will be used to develop and optimize RNA vaccine formulations using Orlance's needle-free MACH-1™ platform.

The MACH-1 platform aims to enhance the safety, stability, and efficacy of RNA vaccines for infectious diseases such as influenza and Covid-19, as well as cancer immunotherapy applications. This technology represents a significant advancement in RNA vaccine delivery compared to traditional methods.

Unlike traditional lipid nanoparticle (LNP) RNA vaccine formulations that require ultra-cold storage and have been associated with rare adverse events like myocarditis, the MACH-1 platform utilizes dry, stable RNA-coated gold microparticles. These microparticles are propelled directly into the epidermis using a burst of pressurized gas. Once they penetrate the skin's outermost layer, they are taken up by immune cells that reside there.

More on Washingtoner
  • Finland's Health Authority Launches '2-4-2' Gambling Risk Limits Ahead of Expected Advertising Boom
  • Evluma Launches RoadMax Edge Streetlight Series, Advancing Urban Illumination and Energy Efficiency
  • Dr. Billy B. Laun II Addresses Over 120 Dental Professionals at Annual Dental Meeting
  • CCHR: Taxpayer Billions Wasted on Mental Health Research as Outcomes Deteriorate
  • Digital Efficiency Consulting Group (DECG) Officially Launches

This needle-free and painless delivery system not only ensures better stability at ambient temperatures but also provides significant supply chain advantages in both developed and low-resource settings. Additionally, it can significantly improve patient comfort and compliance associated with discomfort and fear of needle-based injections.

The SBIR-funded project, titled "Gene Gun-delivered RNA vaccines," will be led by Orlance Principal Investigators Hannah Frizzell, PhD and Kenneth Bagley, PhD. The team aims to optimize RNA formulations for MACH-1 gene gun delivery that maximize loading, maintain functional integrity, and ensure stability and immunogenicity. They will also compare the effectiveness of MACH-1 delivered RNA vaccines against traditional LNP/RNA vaccines in inducing immune responses in preclinical models.

Preliminary studies have shown promising results with MACH-1 delivered RNA vaccines achieving comparable immunogenicity to LNP/RNA vaccines with significantly lower doses. Orlance co-founder and CEO, Kristyn Aalto, explains that while mRNA vaccines have shown great potential in recent years, there is still significant work to be done to improve their utility and global health impact.

More on Washingtoner
  • Work 365 Delivers Purpose-Built Revenue Operations for Microsoft Cloud for US Government
  • Meridianvale Unveils QarvioFin Public Beta: The First 'Glass Box' AI Operating System for Autonomous Finance
  • Impact Space Inc launches I AM AI Ready:Free AI Literacy Platform Bridging the Global Digital Divide
  • Mend Colorado Launches Revamped Sports Performance Training Page
  • Investigation Into North Spokane Shooting That Left Two Dead Continues

The grant will enable Orlance to conduct crucial preclinical studies and pave the way for subsequent phases of development, ultimately leading to clinical trials. Aalto also mentions that Orlance already has a well-developed MACH-1 DNA vaccine candidate portfolio and offering both DNA and RNA vaccine options allows them to provide ideal solutions for specific indications.

Founded in 2016 as a spin-out from the University of Washington (UW), Orlance is focused on developing next-generation MACH-1 vaccines and cancer immunotherapies. With $13M in SBIR funding awarded to date, the company has made significant progress towards readiness for initial regulatory filings in 2024. They plan to initiate Phase I clinical trials for their lead infectious disease asset in 2025 and are actively partnering with other vaccine developers to develop MACH-1 vaccine and immunotherapy candidates across multiple indications.

Orlance's MACH-1 platform has the potential to revolutionize RNA vaccine delivery, making it safer, more stable, and more effective. With the support of NIH's SBIR grant, Orlance is one step closer to achieving their goal of improving global health through innovative genetic vaccines.
Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Roshni Online Services Unveils Plans for Innovative Digital Consultation Platform
  • City of Tacoma Offers In-Person Workshop for Local Businesses on the Revolving Loan Fund Process
  • Wall Street Is Missing This One: Cycurion (NAS DAQ: CYCU) Gets $7 Price Target While Trading at a Steep Discount
  • Aries Industries Streamlines Sewer Inspection Process With Introduction of the LETS Sidewinder
  • Chronic Boss Awards Scholarships to Student Founders Living with Chronic Conditions
  • Nest Finders Property Management Named #1 in Jacksonville and Ranked #99 Nationwide
  • City Council Confirms Appointment of Patti Jackson as Tacoma's Police Chief
  • Nashville International Chopin Piano Competition Launches First Amateur Edition
  • Council Votes on Pathways to Eviction Prevention for Spokane
  • Market Value Enhancement From 2 Important New US Patents Issued for Strengthening Hair Enzyme Booster Technology to Caring Brands (NAS DAQ: CABR)
  • Dr. Billy Laun Will Be Attending An Advanced Airway Management Course by AIME
  • HELM Audio™ Partners with PQCrypto to Future-Proof Children's Hearing and Safety Data Using Post-Quantum Cryptography
  • Wala Blegay to Announce Run for Congress in Maryland's 5th District on Feb. 4
  • Luxury Lake-View Home Launches in Kissimmee's Bellalago community, Offering Privacy, Space, and Florida Resort-Style Living
  • Sleep Basil Launches Revamped Diamond Mattress Collection Page, Highlighting Performance, Craftsmanship, and Personalized Comfort
  • Sleep Basil Curates a Clearer Brooklyn Bedding Experience for Performance-Minded Denver Sleepers
  • Spokane City Council Members Introduce "Immigration Enforcement Free Zones"
  • Spokane: Mayor Brown Calls on Congress to Extend Temporary Protected Status for Haitian Community Members
  • Nevada Man Launches Nationwide Animal Abuse Registry
  • New Threat Management Workshop Brings Hands-On BTAM Training to Spokane Valley
_catLbl0 _catLbl1

Popular on Washingtoner

  • Spokane: Council to Hold Press Conference to Discuss Further Information on Department of Justice Grant - 120
  • TBM Council Appoints U.S. Department of Transportation CDIO Pavan Pidugu to Board of Directors
  • New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year
  • South Spokane Resident Arrives Home To Find Male Burglarizing Apartment; Resident Assaulted Before Suspect Flees The Area
  • Spokane: Male In Custody After Puppy Is Thrown From Moving Vehicle During Argument; Puppy Located By Neighbor Unharmed
  • New Year, New Home: Begin 2026 at Heritage at South Brunswick
  • Tacoma: Dr. Martin Luther King, Jr. Celebration Next Week!
  • Spokane City Council To Hold Special Legislative Session
  • Food Journal Magazine Releases Its 'Best Food In Los Angeles Dining' Editorial Section
  • Yesyal Launches Official Website, Unifying Music, Film, and Apparel Under One Independent Brand

Similar on Washingtoner

  • Finland's Health Authority Launches '2-4-2' Gambling Risk Limits Ahead of Expected Advertising Boom
  • Digital Efficiency Consulting Group (DECG) Officially Launches
  • Work 365 Delivers Purpose-Built Revenue Operations for Microsoft Cloud for US Government
  • Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments
  • Blasting Off with Space Sector Companies: Artemis II Manned Moon Mission is Set to Launch: Could $ASTI be on the Same Rocket Ride as $ASTS & $LUNR?
  • NASA / Glenn Research Center Collaboration to Help Meet Rising Demand for Space Energy Beaming Tech / CIGS PV Modules from Ascent Solar: NAS DAQ: ASTI
  • Half of Finnish Online Gambling Expenditure Now Flows to Offshore Instant Casinos as License Applications Open March 1, 2026
  • Wall Street Is Missing This One: Cycurion (NAS DAQ: CYCU) Gets $7 Price Target While Trading at a Steep Discount
  • Aries Industries Streamlines Sewer Inspection Process With Introduction of the LETS Sidewinder
  • Chronic Boss Awards Scholarships to Student Founders Living with Chronic Conditions
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute